Abstract: There are disclosed various compounds of the formula below, ##STR1## where the parameters R.sub.1 and R.sub.2 are as defined in the specification, which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

Abstract: This invention relates to pyrrolo[2,3-b]indole ketones of the formula ##STR1## where R.sub.1 is loweralkyl, aryl or arylloweralkyl; R.sub.2 is hydrogen, halogen or loweralkyl; R.sub.3 is hydrogen or loweralkyl; R.sub.4 is loweralkyl or arylloweralkyl; R.sub.5 is hydrogen, loweralkyl, loweralkenyl, loweralkynyl, arylloweralkyl, formyl, loweralkylcarbonyl, arylloweralkylcarbonyl or loweralkoxycarbonyl; Y is hydrogen, loweralkyl or loweralkoxy; the pharmaceutically acceptable addition salts thereof, and where applicable, the geometric and optical isomers and racemic mixtures thereof. The compounds of this invention are useful in the treatment of memory impairment characterized by a cholinergic deficit such as that associated with electroshock-induced amnesia and Alzheimer's disease and other senile dementia.

Abstract: Polyfunctional N-cyanoimides and their precursors and derivatives are disclosed along with methods for their preparation and interconversion. Also disclosed are curable compositions comprising the N-cyanoimides or poly(amide-cyanoamides) and reactive diluents as well as novel dianhydrides, polyimides, and poly(amide-cyanoamides) and methods for making them.

Abstract: Novel DC-89 derivatives have an excellent anti-tumor activity, and thus are useful as anti-tumor agent.

Abstract: Mammalian metabilites of the known acetylchloinesterase inhibitor trimethyl-1,3a,8-hexahydro-1,2,3,3a,8,8a-pyrrol[2,3-b]indole-5(3aS,8aR) heptylcarbamate are themselves cholinesterase inhibitors useful in the treatment of various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease and are also useful as analgesic agents in the alleviation of pain.

Abstract: Compounds of the formula ##STR1## are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, and glaucoma.

Abstract: A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.

Abstract: There are disclosed various derivatives related to physostigmine of the formula below, ##STR1## where Z, R.sub.1 and R.sub.2 are as defined in the specification, which compounds are useful for enhancing cholinergic function, and as analgesic agents.

Abstract: 2,7-Diazabicyclo[3.3.0]octanes, suitable for 7-position substituents or antibacterially active quinolone carboxylic acids, of the formula ##STR1## in which R.sup.1, R.sup.3, R.sup.4, R.sup.5, R.sup.7 and R.sup.8 may be identical or different and in each case denote H, C.sub.1 -C.sub.5 -alkyl (optionally substituted by halogen, hydroxyl or C.sub.1 -C.sub.3 -alkoxy), C.sub.1 -C.sub.3 -alkoxycarbonyl or C.sub.6 -C.sub.12 -aryl,R.sup.4 additionally denotes halogen,R.sup.2 and R.sup.6 may be identical or different, denote H, C.sub.1 -C.sub.6 -alkyl, benzyl, C.sub.6 -C.sub.12 -aryl, C.sub.1 -C.sub.3 -alkanoyl, benzoyl or C.sub.1 -C.sub.5 -alkoxycarbonyl, orR.sup.2 and R.sup.3 together denote a bridge of the structure (CH.sub.2).sub.n, n=2-4, CH.sub.2 --CHOH--CH.sub.2, CH.sub.2 --S--CH.sub.2 or C(CH.sub.3).sub.2 --S--CH.sub.2,excluding 2,7-diazabicyclo[3.3.0]octane.Also their preparation by the reaction ##STR2## Intermediates II are also new.

Abstract: This invention relates to compounds of the formula ##STR1## where X is --NH, oxygen, N-loweralkyl, or N-arylloweralkyl; R.sub.1 is hydrogen, loweralkyl, cycloalkyl, aryl, arylloweralkyl, loweralkylene, haloloweralkyl, heteroaryl selected from the group consisting of thienyl, furnayl, pyrrolyl and pyridinyl; heteroarylloweralkyl, heterocyclic selected from piperidinyl, piperazinyl, pyrrolidinyl; or heterocyclicloweralkyl; R.sub.2 is hydrogen or loweralkyl; R.sub.3 is loweralkyl or arylloweralkyl; R.sub.4 is hydrogen, loweralkyl, loweralkenyl, loweralkynyl, arylloweralkyl, formyl, loweralkylcarbonyl, arylloweralkylcarbonyl or loweralkoxycarbonyl; Y is hydrogen, loweralkyl or loweralkoxy, and the pharmaceutically acceptable acid addition salts thereof, and where applicable, the geometric and optical isomers and racemic mixtures thereof.

Abstract: There are disclosed various compounds of the formula below, ##STR1## where the parameters R.sub.1 and R.sub.2 are as defined in the specification, which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

Abstract: The invention concerns heterocyclic nitromethane derivatives of the formula 1 as defined hereinafter (and their non-toxic salts) wherein the heterocyclic moiety Q is thienyl, benzothienyl or dibenzothienyl and may bear a wide variety of optional substituents, together with pharmaceutical compositions containing them. The nitromethane derivatives are inhibitors of the enzyme aldose reductase and are of value in the treatment of certain complications of diabetes and galactosemia.

Abstract: There are disclosed various compounds of the formula below, ##STR1## where X is O, S, NH, N-loweralkyl, or N-arylloweralkyl;Y is hydrogen, fluorine, chlorine, bromine, nitro, loweralkyl, loweralkoxy, or triloweralkylsilyl;R.sub.1 is loweralkyl, halogen-substituted loweralkyl, aryl, arylloweralkyl, cycloalkyl, heteroaryl or heteroarylloweralkyl;R.sub.2 is hydrogen, loweralkyl or arylloweralkyl;R.sub.3 is loweralkyl or arylloweralkyl;R.sub.4 is hydrogen, loweralkyl, loweralkenyl, loweralkynyl, arylloweralkyl, formyl, loweralkylcarbonyl, arylloweralkylcarbonyl or loweralkoxycarbonyl;R.sub.5 is hydrogen or loweralkyl; andm is 0 or 1, with the proviso that when m is O, R.sub.1 may also be hydrogen.which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

Abstract: This invention relates to 4- and 6-carbamates related to physostigmine of the formula ##STR1## where R.sub.1 is alkyl, cycloalkyl, bicycloalkyl, aryl or arylloweralkyl; R.sub.2 is hydrogen or alkyl or the group --NR.sub.1 R.sub.2 taken together forms a monocyclic or bicyclic ring of 5 to 12 carbons; m is 0,1, or 2; each X is independently hydrogen, halogen, loweralkyl, nitro or amino; and the pharmaceutically acceptable acid addition salts thereof, and where applicable, the geometric and optical isomers and racemic mixtures thereof. This invention also relates to novel intermediates useful in the preparation of the 4- and 6-carbamates. The compounds of this invention display utility for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease.

Abstract: There are disclosed various derivatives related to physostigmine of the formula below, ##STR1## where Z, R.sub.1 and R.sub.2 are as defined in the specification, which compounds are useful for enhancing cholinergic function, and as analgesic agents.

Abstract: A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.

Abstract: A renin inhibiting compound of the formula: ##STR1## wherein A is a substituent; R.sub.1 is loweralkyl, loweralkenyl, alkoxyalkyl, [(alkoxy)alkoxy]alkyl, alkoxycarbonylalkyl, carboxyalkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; R.sub.2 is hydrogen, loweralkyl, cycloalkylmethyl or benzyl; D is a substituent; or pharmaceutically acceptable salts or esters thereof.Also disclosed are renin inhibiting compositions, a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.

Abstract: There are disclosed various compounds of the formula below, ##STR1## where X is O, S, NH, H-loweralkyl, or N-arylloweralkyl;Y is hydrogen, fluorine, chlorine, bromine, nitro, loweralkyl, loweralkoxy, or triloweralkylsilyl;R.sub.1 is loweralkyl, halogen-substituted loweralkyl, aryl, arylloweralkyl, cycloalkyl, heteroaryl or heteroarylloweralkyl;R.sub.2 is hydrogen, loweralkyl or arylloweralkyl;R.sub.3 is loweralkyl or arylloweralkyl;R.sub.4 is hydrogen, loweralkyl, loweralkenyl, loweralkynyl, arylloweralkyl, formyl, loweralkylcarbonyl, arylloweralkylcarbonyl or loweralkoxycarbonyl;R.sub.5 is hydrogen or loweralkyl; andm is 0 or 1, with the proviso that when m is O, R.sub.1 may also be hydrogen,which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

Abstract: Organic salts of physostigmine derivatives, having the following general mula: ##STR1## in which R is a linear or branched C.sub.2 -C.sub.12 alkyl or a cycloalkyl or an aryl, and X.sub.- is the anion of an organic acid, the process for their preparation and their pharmaceutical use for acetylcholinesterase inhibition purposes.

Abstract: This invention relates to 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol carbonate esters of the ##STR1## the pharmaceutically acceptable acid addition salts thereof and where applicable to the geometric and optical isomers and racemic mixtures thereof. The compounds of this invention display utility as analgesic agents.

Abstract: There are disclosed various derivatives of physostigmine and related compounds of the formula below, ##STR1## where X, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification, which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

Abstract: There are disclosed various derivatives of physostigmine and related compounds of the formula below, ##STR1## where X,R.sub.1,R.sub.2 and R.sub.3 are as defined in the specification, which compounds are useful for alleviating various memory dysfunctions characterized by a cholinergic deficit such as Alzheimer's disease.

Abstract: Highly potent analogs of (-)-physostigmine are provided which are potent inhibitors of acetylcholinesterase and butyrylcholinesterase. These compounds are useful in treatment of glaucoma, Alzheimer's disease, myasthenia gravis, and organophosphate poisoning.

Abstract: The present invention relates to new naphthyl derivatives of general formula ##STR1## wherein N represents the number 1 or 2,A represents a --CH.sub.2 --, --CO--, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, ##STR2## while the atom marked with an x is linked to the phenyl nucleus, E represents a straight chained alkylene group optionally substituted by an alkyl group,G represents a straight chained alkylene group optionally substituted by an alkyl group,L represents a bond or an oxygen atom, if G represents a straight chained alkylene group with 2 to 5 carbon atoms optionally substituted by an alkyl group,R.sub.1 and R.sub.2, which may be identical or different, represent alkyl or alkoxy groups or R.sub.1 and R.sub.2 together represent an alkylenedioxy group,R.sub.3 represents a hydrogen atom, or an alkyl or an allyl group,R.sub.4, R.sub.5 and R.sub.

Abstract: Physostigmine derivatives with acetylcholinesterase inhibition properties, of general formula: ##STR1## in which R is a linear alkyl of from 2 to 20 C atoms, a branched alkyl, a cycloalkyl or an aryl, when r' is H, or R and R' are linear alkyl of from 2 to 20 C atoms.

Abstract: There are described compounds of the formula ##STR1## where (a) X is O or S;(b) R is H, loweralkyl, ##STR2## where Y is O or S; R.sub.2 is alkyl, cycloalkyl, bicycloalkyl, cycloalkenyl, aryl, arylloweralkyl, heteroaryl or heteroarylloweralkyl, R.sub.3 is H or alkyl, or the group --NR.sub.2 R.sub.3 taken as a whole is 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-piperazinyl, 4-methyl-1-piperazinyl or 2-(2,6-dichlorophenylimino)-1-imidazolidinyl) and R.sub.4 is hydrogen, loweralkyl, arylloweralkyl, diarylloweralkyl, aryl or heteroaryl,(c) m is 1 or 2;(d) each Z is independently H, loweralkyl, halogen, nitro, --NH.sub.2, loweralkylcarbonylamino, arylcarbonylamino, loweralkoxycarbonylamino or loweralkylamino, and(e) R.sub.1 is H, loweralkyl, arylloweralkyl, heteroarylloweralkyl, cycloalkylmethyl or loweralkenylmethyl, with the proviso that when X is O, m is 1, Z is H and R.sub.1 is methyl, R is not --CONHCH.sub.3, --CONHC.sub.6 H.sub.

Abstract: Histamine H.sub.1 receptor antagonists of the formula: ##STR1## in which R.sup.1 and R.sup.2 taken together represent an ortho-fused 1,2-indolo or 2,3-indolo moiety of the formulas: ##STR2## where R.sup.4 is hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or halo; andR.sup.5 is hydrogen, alkyl of 1 to 6 carbon atoms, benzyl, phenyl or substituted phenyl or benzyl where the substituent is taken from the group alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, halo or trifluoromethyl;R.sup.3 is ##STR3## where one X is --N.dbd. and the other is --CH.dbd.;Y is --N.dbd. or --CH.dbd.;and R.sup.6 and R.sup.7 are alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or halo;n is one of the integers 0 or 1;m is one of the integers 0, 1, 2 or 3; ando is one of the integers 1 or 2;or a pharmaceutically acceptable salt thereof.

Abstract: Imide-amides having the structure ##STR1## wherein ##STR2## are certain cycloaliphatic or aromatic groups and R and R individually are hydrogen, halogen, an alkyl group having from 1 to 4 carbon atoms, hydroxy, carboxyl, and amine and when taken together represent ##STR3## wherein R.sup.2 is the same as R and R.sup.1, have been found to provide cured epoxy resin systems characterized by high temperature stability and excellent mechanical and physical properties.

Abstract: Compounds of the formulae I or II ##STR1## and processes for their preparation are described. In the above formulae, Z is a tetravalent aliphatic radical, which can be interrupted by hetero-atoms, or a substituted or unsubstituted tetravalent cycloaliphatic radical, which can contain hetero-atoms and/or can be fused to a benzene ring, A is --C(R.sup.4).dbd.C(R.sup.5)(R.sup.6) or --C.tbd.C--R.sup.5, especially --CH.dbd.CH.sub.2, R.sup.1 and R.sup.2 independenty of one another are H, methyl, phenyl, --CN or Cl, or together are trimethylene, tetramethylene, ##STR2## R.sup.3 is a direct bond, C.sub.1-8 alkylene, cyclohexylene, phenylene or --CH.sub.2 -phenylene with the --CH.sub.2 group bonded to the N atom, R.sup.4 and R.sup.6 independently of one another are H, methyl or ethyl and R.sup.5 is H or C.sub.1-9 alkyl. The compunds of the formula I and II are valuable intermediates for the preparation of silicon-modified adhesion promoters.

Abstract: Novel, unsaturated diacteylene-terminated polyimides and processes for their preparation are disclosed herein. These new polyimides are derivatives of anhydride-terminated aromatic polyimides from which they can be prepared by amidation to provide new unsaturated amide groups having a terminal group containing the structure --C.tbd.C--C.tbd.C--, hereinafter sometimes referred to as "conjugated diynes". These new compositions are more tractable than the original anhydride-terminated polyimides and can be converted at appropriate lower temperatures to crosslinked, insoluble, infusible polymers without by-product formation, thereby extending greatly the applications for which the aromatic polyimides can be employed. Moreover, these new polyimides can undergo the Diels-Alder type of addition with a large number of dienophiles. Certain monomeric materials are also described.

Abstract: Novel, unsaturated diacteylene-terminated polyimides and processes for their preparation are disclosed herein. These new polyimides are derivatives of anhydride-terminated aromatic polyimides from which they can be prepared by amidation to provide new unsaturated amide groups having a terminal group containing the structure --C.tbd.C--C.tbd.C--, hereinafter sometimes referred to as "conjugated diynes". These new compositions are more tractable than the original anhydride-terminated polyimides and can be converted at appropriate lower temperatures to crosslinked, insoluble, infusible polymers without by-product formation, thereby extending greatly the applications for which the aromatic polyimides can be employed. Moreover, these new polyimides can undergo the Diels-Alder type of addition with a large number of dienophiles. Certain monomeric materials are also described.

Abstract: The invention relates to alkanolamido-.beta.-carboxylic acid esters of the formula I ##STR1## A full definition of the above formula will be found in claim 1 of the specification. These compounds are useful stabilizers for chlorinated thermoplastics.

Abstract: Dyestuffs having the general formula: ##STR1## wherein Z.sup.1 and Z.sup.2 each independently represent oxygen or ##STR2## in which Y is hydrogen, an optionally substituted hydrocarbon radical or an acyl radical,R.sup.1 and R.sup.2 each independently represent a substituted or unsubstituted aryl radical, preferably phenyl, andX.sup.1 and X.sup.2 each independently represent hydrogen, halogen, cyano, alkyl, alkoxy, nitro, amino, substituted amino, carboxylic acid, carboxylic acid ester, optionally substituted carbamoyl, alkylthio, arylthio, alkylsulphonyl, arylsulphonyl, acyl, acyloxy, hydroxy, sulphonic acid or sulphonic acid ester, orX.sup.1 and X.sup.2 together form a 5- or 6-membered, carbocyclic or heterocyclic, saturated or unsaturated, including aromatic, ring which may carry further substituents; processes for the manufacture of these dyestuffs and their use for coloring aromatic polyester textile materials.